EDGAR·FLOW

Retension Pharmaceuticals, Inc. — Form 8-K

Filed November 18, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 48/100
What the filing says
Retension Pharmaceuticals (Nasdaq: RTSN), a clinical-stage biopharma company, completed its IPO in October 2026, issuing 4,312,500 shares at $12/share for $51.75M gross proceeds ($45.1M net). The company is developing RTN-001 for hypertension, with Phase 2b topline data expected in H1 2027. Pro forma cash position as of September 30, 2026 was $54.3M; Q3 2026 net loss was $5.9M (vs. $1.5M in Q3 2025), driven by Phase 2b trial costs.
Why this rating

IPO closes major financing gap for early-stage biotech; $45M net proceeds substantially funds Phase 2b and Phase 3 runway. However, company pre-revenue, heavily cash-dependent, and binary on RTN-001 trial outcome. Material for a clinical-stage company but typical early-stage biopharma risk.

View original filing on SEC.gov ↗ RTSN · stock on Yahoo Finance ↗

See more from November 18, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.